NASDAQ:ALLO

Allogene Therapeutics Stock Predictions

etoro logo Buy ALLO
*Your capital is at risk
$2.00
-0.0500 (-2.44%)
At Close: Jun 03, 2026
Currently predicting for Thu, 4 Jun 2026

ALLO Prediction Chart

ALLO Predictions History

Latest community submissions for ALLO.
Predictor Target Session Target Price Result Direction Accuracy Score
Mar 25, 2026 $2.12 -4.18% $2.33 X 90.88% 0
Mar 25, 2026 $2.27 +2.61% $2.33 V 97.33% 1
Mar 25, 2026 $2.50 +2.46% $2.33 X 92.70% 1
Feb 26, 2026 $2.46 -2.79% $2.73 X 90.09% 0
Feb 26, 2026 $2.49 -1.74% $2.73 X 91.06% 0
Feb 26, 2026 $2.50 -1.19% $2.73 X 91.58% 0
Feb 25, 2026 Bullish $2.53 V 1
Feb 25, 2026 $2.22 -2.94% $2.53 X 87.85% 0
Feb 25, 2026 $2.25 -1.84% $2.53 X 88.85% 0
Feb 25, 2026 Bullish $2.53 V 1
Click to get the best stock tips daily for free!
Forecast Desk

Request A 3-Month Forecast

Ask an approved predictor to map the next 66 trading days for ALLO with a full price path, not just a one-day call.
  • Price path
  • Approved predictor
  • 3-month horizon
ABOUT ALLOGENE THERAPEUTICS INC.
Allogene Therapeutics
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic ...
GOLDEN STAR
Ticker Change Signal Date
RUN
$12.83
18.86% May 06
GLBE
$31.61
5.35% May 05
SAP
$172.39
10.69% May 05
W
WCLD
$27.34
27.18% Apr 29
ADBE
$243.57
7.61% Apr 29

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE